Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priel

Showing results (391-400 of 433) with videos related to

Pageof 44
Sort By:
Blood|March 10, 2012
Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infectionSarah K Browne, Rifat Zaman, Elizabeth P Sampaio, et al.
Nature Medicine|May 26, 2015
Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-αIvan D Mascanfroni, Maisa C Takenaka, Ada Yeste, et al.
Frontiers in Immunology|September 11, 2025
Reliable genetic diagnosis of <i>NCF1</i> (p47<sup>phox</sup>)-deficient chronic granulomatous disease using high-throughput sequencingAmy P Hsu, Eric Karlins, Justin Lack, et al.
Circulation Research|December 25, 2015
Critical Role for Telomerase in the Mechanism of Flow-Mediated Dilation in the Human MicrocirculationAndreas M Beyer, Julie K Freed, Matthew J Durand, et al.
The New England Journal of Medicine|December 31, 2010
Residual NADPH oxidase and survival in chronic granulomatous diseaseDouglas B Kuhns, W Gregory Alvord, Theo Heller, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2021
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studiesMark W Skinner, Claude Négrier, Ido Paz-Priel, et al.
The New England Journal of Medicine|August 30, 2018
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsJohnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, et al.
Blood Advances|January 18, 2019
<i>NCF1</i> (p47<sup>phox</sup>)-deficient chronic granulomatous disease: comprehensive genetic and flow cytometric analysisDouglas B Kuhns, Amy P Hsu, David Sun, et al.
Plos One|November 14, 2013
A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biologyMatteo M Trucco, Ola Awad, Breelyn A Wilky, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 8, 2014
An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous diseaseRandall K Merling, Colin L Sweeney, Jessica Chu, et al.
Pageof 44

Showing results (391-400 of 433) with videos related to

Sort By:
Pageof 44
Blood|March 10, 2012
Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infectionSarah K Browne, Rifat Zaman, Elizabeth P Sampaio, et al.
Nature Medicine|May 26, 2015
Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-αIvan D Mascanfroni, Maisa C Takenaka, Ada Yeste, et al.
Frontiers in Immunology|September 11, 2025
Reliable genetic diagnosis of <i>NCF1</i> (p47<sup>phox</sup>)-deficient chronic granulomatous disease using high-throughput sequencingAmy P Hsu, Eric Karlins, Justin Lack, et al.
Circulation Research|December 25, 2015
Critical Role for Telomerase in the Mechanism of Flow-Mediated Dilation in the Human MicrocirculationAndreas M Beyer, Julie K Freed, Matthew J Durand, et al.
The New England Journal of Medicine|December 31, 2010
Residual NADPH oxidase and survival in chronic granulomatous diseaseDouglas B Kuhns, W Gregory Alvord, Theo Heller, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2021
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studiesMark W Skinner, Claude Négrier, Ido Paz-Priel, et al.
The New England Journal of Medicine|August 30, 2018
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsJohnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, et al.
Blood Advances|January 18, 2019
<i>NCF1</i> (p47<sup>phox</sup>)-deficient chronic granulomatous disease: comprehensive genetic and flow cytometric analysisDouglas B Kuhns, Amy P Hsu, David Sun, et al.
Plos One|November 14, 2013
A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biologyMatteo M Trucco, Ola Awad, Breelyn A Wilky, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 8, 2014
An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous diseaseRandall K Merling, Colin L Sweeney, Jessica Chu, et al.
Pageof 44